Uveitis Therapy Landscape: Emerging Drugs and Their Potential Impact

Uveitis refers to inflammation of the uveal tract, which includes the iris, ciliary body, and choroid. In many cases, the inflammation also affects nearby structures like the sclera, retina, cornea, optic nerve, and vitreous humor. Often caused by autoimmune responses or infections, uveitis is a major contributor to global visual disability, accounting for 10–15% of all blindness cases. More than one-third of those diagnosed experience some degree of vision impairment. Anterior uveitis is the most common form, representing nearly half of all cases, while posterior uveitis remains the least diagnosed.

???? Uncover critical insights into epidemiology, market trends, and innovation in our visual Uveitis Market snapshot.

Epidemiology Overview (2020–2034, 7MM)

Total diagnosed prevalent population

Type-specific breakdown

Anatomical classification-based segmentation

Prevalence by etiology

Epidemiology Highlights
In 2022, roughly 1 million individuals across the 7 major markets (7MM) were diagnosed with uveitis. The U.S. accounted for approximately 378,000 of these cases, or about 37.5% of the total burden. Spain recorded the lowest prevalence, contributing just 7%. Within the U.S., noninfectious uveitis (NIU) far outnumbered infectious uveitis (IU), with 344,587 cases of NIU and 33,695 IU cases. These numbers are projected to climb over the forecast period.

Uveitis Market Landscape
The uveitis market in the 7MM was valued at around USD 1.4 billion in 2022.

Key Growth Drivers

Novel therapies with improved targeting and delivery systems are expanding treatment options and improving patient outcomes.

Better understanding of disease mechanisms is allowing for the development of more personalized treatment approaches.

Challenges Limiting Market Potential

Side effects from current therapies often hinder long-term use.

Limited randomized clinical trial data and widespread use of off-label treatments restrict the creation of standard care protocols.

Emerging Therapeutics in Uveitis
Several promising candidates are advancing through the pipeline, including:

TRS01

Licaminlimab

Vamikibart

OLUMIANT

EYS606

Izokibep

Brepocitinib

OCS-01

And more

Key Players Driving Innovation
Major pharmaceutical and biotech companies involved in uveitis research and development include:

Tarsier Pharma

Oculis Pharma

Roche

Eleven Biotherapeutics

Eli Lilly and Company

Eyevensys

Acelyrin

Affibody Medical

Priovant Therapeutics

Among others

???? Download the full Uveitis Market Forecast Report to explore the latest treatment landscape, pipeline activity, and strategic market intelligence.